Tirzepatide plus HRT for perimenopause: what the evidence says

What's this video probably claiming?

Based on the caption, hashtags, and the med spa tag, this video almost certainly presents compounded tirzepatide alongside hormone replacement therapy as a combined protocol for women in perimenopause. The framing is likely testimonial-style: weight coming off, energy returning, hormones finally "balanced." Creators in this space typically credit the GLP-1 for fat loss and HRT for mood, sleep, and libido improvements, then attribute the whole package to the clinic. The med spa tag (Patuxent Integrative Wellness) suggests this is partly promotional content for a compounding-friendly practice. That matters because compounded tirzepatide is not FDA-approved, and the combination protocol being described is not backed by randomized controlled trial data specific to perimenopausal women. The video probably doesn't mention any of that.

What does the science actually show?

Tirzepatide's weight loss data is genuinely strong. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed 20.9% mean body weight reduction over 72 weeks at the 15 mg dose in adults with obesity. For HRT in perimenopause, the data supports symptom relief, specifically vasomotor symptoms and sleep disruption, not weight loss as a standalone effect. The 2022 NAMS position statement acknowledges estrogen therapy's role in vasomotor symptom management but stops well short of endorsing it for metabolic transformation. Where it gets interesting: estrogen does influence fat distribution and insulin sensitivity. A 2021 review by Davis et al. in The Lancet Diabetes and Endocrinology noted that estrogen loss accelerates visceral fat accumulation, which theoretically makes GLP-1 therapy more relevant in this population. But "theoretically relevant" is not the same as "clinically proven in combination."

Where does the social media noise diverge from clinical reality?

The biggest gap is attribution. When someone combines tirzepatide with HRT, loses weight, and feels better, there is no way to know which intervention did what without a controlled comparison. Social media content treats the protocol as the explanation. That's not science, that's a before-and-after photo. Second, compounded tirzepatide is not the same as Zepbound or Mounjaro. The FDA has warned repeatedly that compounded versions have not been evaluated for safety or efficacy. Compounded tirzepatide was removed from the FDA's drug shortage list in 2024, which means most compounding is now legally questionable. Clinics promoting it as equivalent to brand-name tirzepatide are misrepresenting the regulatory status. Third, the dose titration shown in these videos is often aggressive. Starting doses, side effect management, and monitoring protocols vary wildly between med spas and regulated telehealth providers.

What should you actually know?

If you are a perimenopausal woman considering this combination, a few things deserve honest attention. GLP-1 agonists can cause significant muscle mass loss alongside fat loss, which is already a concern during menopause when lean mass preservation matters. A 2023 paper by Wilding et al. in Obesity Reviews flagged this and recommended resistance training alongside GLP-1 therapy. HRT, specifically estradiol, may actually complement GLP-1 effects on insulin sensitivity, but this has not been tested in adequately powered trials. The promotional framing of med spa content tends to skip past side effects, monitoring requirements, and the fact that stopping tirzepatide typically results in weight regain (SURMOUNT-4, Aronne et al., 2024, JAMA). The combination may be reasonable for some women. The issue is that social media makes it sound proven, simple, and without trade-offs. None of those things are true.